Office of Research Seminar Series: E-Cigarettes in Smoking Harm Reduction

May 01
3:30-4:30pm
708 Broadway, Room 801 / Online

Hosted by the GPH Office of Research

Join Dr. Omar El-Shahawy from the NYU Langone Department of Population Health, for a guest seminar, “E-cigarettes in Smoking Harm Reduction: Evaluating Implementation Challenges Among Three Hard-to-Treat Populations." This talk will cover Dr. El-Shahawy’s research pertaining to e-cigarettes use for smoking harm reduction in different clinical settings, as well as the regulatory and system challenges in incorporating e-cigarettes in tobacco treatment, with specific discussion on the implementation and findings of three randomized clinical trials.

About the Speaker:
Omar El-Shahawy, MD, MPH, PhD is a behavioral researcher who focus extensively on developing high impact multi-modal interventions, using mixed-methods approaches and informed by behavioral change theories, primarily targeting smoking cessation and harm reduction in nicotine addiction. He is currently an Assistant Professor in the NYU School of Medicine, Department of Population, Section on Tobacco, Alcohol and Drug Use. He also holds an affiliated faculty position at the NYU GPH Division of Global Health.

Dr. El-Shahawy obtained his medical degree at the University of Ain Shams in Cairo, Egypt, in 2002 and his Master of Public Health in international health development from the Royal Tropical Institute in Amsterdam, Netherlands, in 2007. He was awarded the prestigious Hubert Humphrey fellowship in substance abuse education, treatment, and prevention from the Department of State and National Institute on Drug Abuse (NIDA) in 2010. He later obtained his PhD in Social and Behavioral Health Sciences from Virginia Commonwealth University in 2015. During his postdoctoral fellowship at NYU School of Medicine, Dr. El Shahawy focused on alternative tobacco product use among vulnerable populations including people with substance use disorders. His current research interests include epidemiology of novel tobacco products, tobacco treatment among vulnerable populations, incorporating telehealth strategies to support non-communicable disease management, and patient-physician decision making.